The future of the EMA? A question of sustainability

You are missing some Flash content that should appear here! Perhaps your browser cannot display it, or maybe it did not initialise correctly.

Following the Ernst and Young evaluation of the European Medicines Agency, a conference was held on 30 June in London to discuss its findings and recommendations for the future. The focus of the research was the Centralised Procedure and referrals. Although the EMA is delivering an increasing number of highly valued opinions of good quality involving the best experts in Europe, the number of applications has doubled since 2005 and the main committees are ‘overwhelmed with work’. Discussing these and other major challenges affecting EMA were representatives from the Agency, E&Y, the Commission, national agencies from across Europe, the European Parliament, industry trade associations, professional representatives (doctors etc) and patient organisations. Lynda Wight attended on behalf of TOPRA and her full report of the outcomes can be accessed here.